Skip to main content
OpenTrials
Completed

NCT Number: NCT03338218

Safety and Efficacy of a 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Trauma Patients

The aim of the study is to investigate the safety of a 6% hydroxyethyl starch (HES) solution (Volulyte 6%) versus an electrolyte solution (Ionolyte) in trauma patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Ziekenhuis Oost-Limburg-ZOL, Genk, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion:

  • Male or female adult patients ≥18 years of age. Women of child bearing potential must test negative on standard pregnancy test (urine or serum) (as soon as possible during emergency care)
  • Patients with blunt or penetrating trauma suffering from estimated blood loss of ≥ 500 ml
  • Initial surgery deemed necessary within 24 hrs after trauma
  • Deferred signed written informed consent form or as locally required
  • No signs of intracranial or cerebral hemorrhage
  • Administration of less than 15 ml/kg body weight colloid between trauma injury and hospital admission.

Exclusion:

  • Hypersensitivity to the active substances or to any of the other excipients of the Investigational Products
  • Body weight ≥ 140 kg
  • Patients expected to die within 24h after traumatic injury
  • Sepsis
  • Burns
  • Renal impairment (AKIN stage ≥ 1 or chronic) or acute and/or chronic Renal Replacement Therapy
  • Critically ill patients (typically admitted to the intensive care unit)
  • Hyperhydration
  • Pulmonary edema
  • Dehydration
  • Hyperkalemia
  • Severe hypernatremia
  • Severe hyperchloremia
  • Severely impaired hepatic function
  • Congestive heart failure
  • Severe coagulopathy
  • Organ transplant patients
  • Metabolic alkalosis
  • Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)

Treatment and study plan

Volulyte 6%

Drug

Solution for infusion

Other names: Hydroxyethyl starch 130

Ionolyte

Drug

Solution for infusion

Other names: Ionolyte Electrolyte Solution

Primary outcomes

  1. Composite endpoint of 90 day mortality and 90 day renal failure defined as biomarker increase as defined by AKIN stage 2 or RIFLE injury stage or need for RRT at any time during the first 3 months.

    Time frame: 90 days

Secondary outcomes

  1. Serum creatinine

    Time frame: 7 days post-trauma

  2. Serum creatinine-based estimated glomerular filtration rate

    Time frame: 7 days post-trauma

  3. Cystatin-C

    Time frame: 3 days post-trauma

  4. Cystatin-C-based mean estimated glomerular filtration rate

    Time frame: 3 days post-trauma

  5. AKIN stages

    Time frame: 7 days post-trauma

  6. Highest AKIN stage reached on each day during the first week

    Time frame: 7 days post-trauma

  7. RIFLE stages

    Time frame: 7 days post-trauma

  8. Urine output (if available)

    Time frame: 7 days post-trauma

  9. Days on Renal Replacement Therapy

    Time frame: 90 days after randomization

  10. Patients on Renal Replacement Therapy

    Time frame: 90 days after randomization

  11. Platelet count

    Time frame: 3 days post-trauma

  12. International normalized ratio

    Time frame: 3 days post-trauma

  13. Activated partial thromboplastin time

    Time frame: 3 days post-trauma

  14. Adverse Events

    Time frame: 90 days after randomization

  15. Mortality

    Time frame: 90 days after randomization

  16. Length of Stay in ICU/hospital

    Time frame: 90 days after randomization

  17. C-reactive protein

    Time frame: 3 days post-trauma

  18. Hours on mechanical ventilation

    Time frame: 7 days post-trauma

  19. Total volume of administered investigational products

    Time frame: until 24 hours after investigational product treatment start

  20. Fluid balance

    Time frame: 7 days post-trauma

    Sum of volume of all intravenous medication (including investigational product and blood products) minus sum of volume of urine output (if available), drainage and estimated due to surgeries and trauma

  21. Heart rate

    Time frame: 7 days post-trauma

  22. Temperature

    Time frame: 7 days post-trauma

  23. Mean arterial pressure

    Time frame: 7 days post-trauma

  24. Systolic arterial blood pressure

    Time frame: 7 days post-trauma

  25. Diastolic arterial blood pressure

    Time frame: 7 days post-trauma

  26. Central venous pressure (if available)

    Time frame: 7 days post-trauma

  27. Partial pressure of carbon dioxide

    Time frame: 3 days post-trauma

  28. Partial pressure of oxygen

    Time frame: 3 days post-trauma

  29. Bicarbonate

    Time frame: 3 days post-trauma

  30. Arterial oxygen saturation

    Time frame: 3 days post-trauma

  31. Hemoglobin

    Time frame: 3 days post-trauma

  32. Hematocrit

    Time frame: 3 days post-trauma

  33. pH

    Time frame: 3 days post-trauma

  34. Base excess

    Time frame: 3 days post-trauma

  35. Lactate

    Time frame: 3 days post-trauma

  36. Central venous oxygen saturation (if available)

    Time frame: 3 days post-trauma

  37. Serum sodium

    Time frame: 3 days post-trauma

  38. Serum potassium

    Time frame: 3 days post-trauma

  39. Serum calcium

    Time frame: 3 days post-trauma

  40. Serum chloride

    Time frame: 3 days post-trauma

Sponsors and collaborators

Lead sponsor

Fresenius Kabi

Industry

Collaborators

  • B. Braun Melsungen AG
  • European Society of Anaesthesiology and Intensive Care

Registry information

Official study title

Pragmatic, Prospective, Randomized, Controlled, Double-blind, Multi-centre, Multinational Study on the Safety and Efficacy of a 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Trauma Patients

Acronym: TETHYS

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Nov 9, 2017
Registry last updated
Aug 5, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.